RayKnowChina Research Map
Shortlist

Cancer

Breast cancer in Guangzhou

广州 乳腺癌

All diseases in Guangzhou

17 hospitals in Guangzhou

Order: papers led on breast cancer, 2021–2025, then A–Z. Research activity, not a rating of care.

Only hospitals listed for breast cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Guangzhou may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.

  1. 222 papers led
  2. 135 papers led
  3. 96 papers led
  4. 83 papers led
  5. 57 papers led
    No open trial led
  6. 50 papers led
  7. 49 papers led
  8. 30 papers led
    No open trial led
  9. 24 papers led
    No open trial led
  10. 20 papers led
    No open trial led
  11. 19 papers led
    No open trial led
  12. 16 papers led
  13. 16 papers led
  14. 13 papers led
    No open trial led
  15. 8 papers led
  16. 4 papers led
    No open trial led
  17. 0 papers led
    No open trial led

Breast cancer in every city Guangzhou on the disease page, with the national map

139

open trials on breast cancer with a hospital in Guangzhou

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Guangzhou as lead sponsor or study site. 85 of them are led by a hospital in Guangzhou. Check the registry for the current status. Whether someone can take part is decided by the study team.

Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.

  1. Recruiting
    A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07281976

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Guangzhou, Harbin, Nanjing, Shenyang, Zhengzhou

  2. Recruiting
    A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07347600

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Weifang, Wuhan, Xi'an, Xiamen, Yangzhou, Zhengzhou

  3. Recruiting
    A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Cancer
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07352930

    Age 18 years to Not stated; women only (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  4. Recruiting
    FMD and Neoadjuvant Chemo-immunotherapy in TNBC
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07378306

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  5. Recruiting
    Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
    Phase
    Phase 3
    Started
    2026-02
    Posted
    Registry
    NCT07400523

    Age 18 years to Not stated; women only (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 2 listed hospitals as study sitesGuangzhou, Shantou, Zhanjiang

  6. Recruiting
    Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy
    Phase
    Phase 2/Phase 3
    Started
    2026-09
    Posted
    Registry
    NCT07410169

    Age 18 years to 75 years; women only (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  7. Recruiting
    RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07413939

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shantou, Tianjin, Urumqi, Wuhan

  8. Recruiting
    BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07492641

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou

  9. Recruiting
    Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07498478

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Linyi, Nanjing, Shanghai, Tianjin, Wuhan

  10. Recruiting
    Large Language Models Assist in Tumor MDT
    Phase
    N/A
    Started
    2026-01
    Posted
    Registry
    NCT07504367

    Age 25 years to 33 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  11. Recruiting
    A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07518173

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Guangzhou

  12. Recruiting
    A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07520760

    Age 18 years to Not stated; women only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  13. Recruiting
    A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07533123

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  14. Recruiting
    Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer
    Phase
    Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07543536

    Age 18 years to 75 years; women only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  15. Recruiting
    A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07544056

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangsha, Guangzhou

  16. Recruiting
    Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07610720

    Age 18 years to 75 years; women only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  17. Recruiting
    Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects
    Phase
    Phase 1/Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07697443

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chengdu, Guangzhou, Meizhou, Tianjin, Wuhan

  18. Recruiting
    SMP-656 for HER2-Positive Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07726342

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shenyang, Shijiazhuang, Wuhan, Xi'an, Zhengzhou

  19. Recruiting
    Culmerciclib in HR+/HER2+ Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07732491

    Age 18 years to Not stated; women only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  20. Recruiting
    A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07757230

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  21. Recruiting
    Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07796880

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  22. Recruiting
    A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07876557

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Jinan, Lanzhou, Nanchang, Nanjing, Qingdao, Shenyang, Shijiazhuang, Taiyuan, Weifang, Wuhan, Yinchuan, Zhengzhou

  23. Recruiting
    Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
    Phase
    Not given
    Started
    2026-10
    Posted
    Registry
    NCT07880106

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  24. Recruiting
    A Phase II Clinical Trial of Artificial Intelligence-assisted One-stop Radiotherapy for Breast Cancer After Breast-conserving Surgery
    Phase
    N/A
    Started
    2025-04
    Posted
    Registry
    NCT06686459

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  25. Recruiting
    BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
    Phase
    Phase 1
    Started
    2025-02
    Posted
    Registry
    NCT06756932

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai, Tianjin, Zhengzhou

  26. Recruiting
    A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06790693

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Kunming, Nanning, Tianjin, Urumqi, Xi'an, Xiangyang

  27. Recruiting
    A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Breast Cancer Patients
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06811870

    Age 18 years to 60 years; women only (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  28. Recruiting
    A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06841354

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanjing, Nanning, Taiyuan, Taizhou, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  29. Recruiting
    The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06851299

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  30. Recruiting
    Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
    Phase
    Phase 3
    Started
    2025-02
    Posted
    Registry
    NCT06889688

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 4 listed hospitals as study sitesChangsha, Guangzhou, Guiyang, Shanghai, Wuhan

  31. Recruiting
    A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06891833

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesAnyang, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Luoyang, Nanchang, Nanning, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  32. Recruiting
    Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients
    Phase
    N/A
    Started
    2025-08
    Posted
    Registry
    NCT06892093

    Age 18 years to Not stated; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  33. Recruiting
    Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
    Phase
    Phase 1
    Started
    2025-01
    Posted
    Registry
    NCT06900647

    Age 18 years to Not stated; women only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  34. Recruiting
    Study on the Use of Lateral Decubitus Position in Left Breast Cancer Patients Undergoing Adjuvant Radiotherapy
    Phase
    N/A
    Started
    2025-04
    Posted
    Registry
    NCT06902051

    Age 18 years to 70 years; women only (registered criteria)

    Led by Nanfang HospitalGuangzhou

  35. Recruiting
    A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
    Phase
    Phase 2/Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT06926868

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesAnyang, Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanning, Qingdao, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou

  36. Recruiting
    A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2025-05
    Posted
    Registry
    NCT06957886

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangsha, Guangzhou

  37. Recruiting
    Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06992336

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  38. Recruiting
    Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06993844

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesFuzhou, Guangzhou, Jinan, Shanghai

  39. Recruiting
    The Application of "HUAXI Hole 1" in Reverse-sequence Endoscopic Nipple-sparing Mastectomy With Direct-to-implant Breast Reconstruction
    Phase
    N/A
    Started
    2025-06
    Posted
    Registry
    NCT06995118

    Age 18 years to 70 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangchun, Chengdu, Fuzhou, Guangzhou, Nanchang, Zhengzhou

  40. Recruiting
    A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07024173

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangsha, Guangzhou

  41. Recruiting
    Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07037199

    Age 18 years to Not stated; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  42. Recruiting
    A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07043725

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 52 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Harbin, Hefei, Hengyang, Jinan, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Xinxiang, Yantai, Zhengzhou

  43. Recruiting
    A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07060807

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Taizhou, Urumqi, Xi'an, Xiamen, Xiangyang, Zhengzhou

  44. Recruiting
    A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07062965

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Wenzhou, Wuhan, Xi'an

  45. Recruiting
    Modulating the Skin Microbiome to Prevent Radiation Dermatitis in Breast Cancer
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT07066280

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  46. Recruiting
    A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07071337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Guangzhou

  47. Recruiting
    Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07088263

    Age 18 years to 75 years; women only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  48. Recruiting
    Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
    Phase
    N/A
    Started
    2025-08
    Posted
    Registry
    NCT07095023

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Guiyang, Shantou, Shenzhen, Wenzhou

  49. Recruiting
    A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07169994

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesAnyang, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Luoyang, Meizhou, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Xiangyang

  50. Recruiting
    A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07174336

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Harbin, Shanghai, Shantou, Tianjin, Wuhan

  51. Recruiting
    Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07258108

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  52. Recruiting
    A Retrospective Analysis of Robot-Assisted Versus Endoscopic Breast-Conserving Surgery for Breast Cancer
    Phase
    N/A
    Started
    2025-06
    Posted
    Registry
    NCT07321145

    Age 18 years to 80 years; women only (registered criteria)

    Led by Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  53. Recruiting
    Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer
    Phase
    Not given
    Started
    2025-06
    Posted
    Registry
    NCT07358182

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  54. Recruiting
    Acupuncture and Compression for the Prevention of CIPN in Breast Cancer Patients
    Phase
    N/A
    Started
    2025-09
    Posted
    Registry
    NCT07377279

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  55. Recruiting
    Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07401537

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  56. Recruiting
    Endoscopic Skin-Sparing vs. Conventional Mastectomy for Wound Complications in BC
    Phase
    N/A
    Started
    2025-12
    Posted
    Registry
    NCT07548762

    Age 18 years to 75 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  57. Recruiting
    A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT07673029

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 51 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Meizhou, Nanchang, Nanning, Qingdao, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xi'an, Xinxiang, Xuzhou, Yantai, Zhengzhou

  58. Recruiting
    Organoid-based Functional Precision Therapy for Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06102824

    Age 18 years to 80 years (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  59. Recruiting
    A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
    Phase
    Phase 2
    Started
    2024-02
    Posted
    Registry
    NCT06172478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Guangzhou

  60. Recruiting
    A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
    Phase
    Not given
    Started
    2024-01
    Posted
    Registry
    NCT06210776

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Kunming, Luoyang, Nanchang, Nanjing, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Taiyuan, Tangshan, Tianjin, Urumqi, Weifang, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou, Zhuhai

  61. Recruiting
    Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2024-06
    Posted
    Registry
    NCT06255392

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  62. Recruiting
    Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy
    Phase
    Phase 3
    Started
    2024-03
    Posted
    Registry
    NCT06313463

    Age 18 years to 80 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  63. Recruiting
    Minimal Access Versus Conventional Latissimus Dorsi Flap Harvest for Breast Reconstruction
    Phase
    N/A
    Started
    2024-03
    Posted
    Registry
    NCT06319157

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  64. Recruiting
    The Impact of Socioeconomic Determinants on the Patient Reported Outcomes in Young Breast Cancer Patients After Breast Surgery
    Phase
    Not given
    Started
    2024-02
    Posted
    Registry
    NCT06425874

    Age 18 years to 50 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  65. Recruiting
    A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Posted
    Registry
    NCT06465069

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

  66. Recruiting
    PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC
    Phase
    Phase 3
    Started
    2024-08
    Posted
    Registry
    NCT06533384

    Age 18 years to 70 years; women only (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  67. Recruiting
    The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer
    Phase
    Phase 4
    Started
    2024-10
    Posted
    Registry
    NCT06641544

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  68. Recruiting
    Arsenous Acid for Refractory Triple-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06678048

    Age 18 years to 75 years; women only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  69. Recruiting
    Long-Term Outcomes of Endoscopic-assisted vs Conventional Breast-conserving Surgery in Breast Cancer Patients After Neoadjuvant Therapy: a Randomized, Multicenter, Open Label, Non-inferiority Trial
    Phase
    N/A
    Started
    2024-08
    Posted
    Registry
    NCT06716073

    Age 18 years to 75 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  70. Recruiting
    The Optimal Radioimmunotherapy Combinations for Advanced TNBC
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06735131

    Age not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  71. Recruiting
    A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05646862

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Tianjin, Wuhan

  72. Recruiting
    Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
    Phase
    Phase 3
    Started
    2023-10
    Posted
    Registry
    NCT05696626

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 57 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Kunming, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  73. Recruiting
    Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2023-04
    Posted
    Registry
    NCT05744687

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesAnyang, Beijing, Changchun, Fuzhou, Guangzhou, Luoyang, Yinchuan

  74. Recruiting
    Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
    Phase
    Phase 3
    Started
    2023-03
    Posted
    Registry
    NCT05760612

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  75. Recruiting
    Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2023-09
    Posted
    Registry
    NCT05860465

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanjing, Shenyang, Shijiazhuang, Tianjin, Xi'an, Yinchuan

  76. Recruiting
    Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
    Phase
    Phase 2
    Started
    2023-09
    Posted
    Registry
    NCT05872347

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Guangzhou, Hangzhou, Harbin, Hefei, Luoyang, Nanjing, Nanning, Shijiazhuang, Tianjin, Urumqi, Wuhan, Xiangyang, Yinchuan, Zhengzhou

  77. Recruiting
    Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05891093

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 13 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nantong, Ningbo, Shanghai, Shenyang, Xi'an, Yangzhou

  78. Recruiting
    Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)
    Phase
    Phase 3
    Started
    2023-07
    Posted
    Registry
    NCT05904964

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 1 listed hospital as study siteGuangzhou, Shantou

  79. Recruiting
    Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05909332

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 13 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nantong, Ningbo, Shanghai, Shenyang, Xi'an, Yangzhou

  80. Recruiting
    Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2023-08
    Posted
    Registry
    NCT05981001

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  81. Recruiting
    Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2023-08
    Posted
    Registry
    NCT05981014

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  82. Recruiting
    A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
    Phase
    Phase 1/Phase 2
    Started
    2023-09
    Posted
    Registry
    NCT06064812

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesChangchun, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

  83. Recruiting
    JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06079983

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 60 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Hengyang, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Meizhou, Nanchang, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xining, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi

  84. Recruiting
    A Study of YL202 in Selected Patients With Advanced Solid Tumors
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06107686

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jinan, Meizhou, Nanchang, Nanning, Qingdao, Shanghai, Shantou, Shenyang, Suzhou, Taiyuan, Taizhou, Urumqi, Weifang, Wuhan, Xi'an, Xiangyang, Xuzhou, Zhengzhou

  85. Recruiting
    BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2023-12
    Posted
    Registry
    NCT06120283

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shanghai, Shenyang

  86. Recruiting
    Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
    Phase
    Phase 1
    Started
    2023-11
    Posted
    Registry
    NCT06121557

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  87. Recruiting
    Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
    Phase
    Phase 1
    Started
    2023-11
    Posted
    Registry
    NCT06121570

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  88. Recruiting
    Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06167694

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Guangzhou

  89. Recruiting
    Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
    Phase
    Phase 3
    Started
    2023-09
    Posted
    Registry
    NCT06278870

    Age 18 years to 75 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  90. Recruiting
    AI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes Tumors
    Phase
    Not given
    Started
    2023-03
    Posted
    Registry
    NCT06286267

    Age not stated; women only (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 1 listed hospital as study siteGuangzhou

  91. Recruiting
    EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer
    Phase
    Early phase 1
    Started
    2022-05
    Posted
    Registry
    NCT05341492

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  92. Recruiting
    A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2022-08
    Posted
    Registry
    NCT05461768

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Guangzhou, Jinan, Wuhan, Zhengzhou

  93. Recruiting
    A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2022-08
    Posted
    Registry
    NCT05470348

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai

  94. Recruiting
    Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05579366

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan

  95. Recruiting
    Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation
    Phase
    Phase 2
    Started
    2022-05
    Posted
    Registry
    NCT05761470

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  96. Recruiting
    A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2022-01
    Posted
    Registry
    NCT05851014

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an, Yinchuan, Zhengzhou

  97. Recruiting
    Cold Dissection Versus Electrocautery Dissection in Endoscopic Nipple-Sparing Mastectomy and Immediate Implant-Based Reconstruction: A Randomized Controlled Trial
    Phase
    N/A
    Started
    2022-11
    Posted
    Registry
    NCT06024187

    Age 18 years to 75 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  98. Recruiting
    Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
    Phase
    Not given
    Started
    2022-10
    Posted
    Registry
    NCT06551220

    Age 18 years to 80 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Foshan, Fuzhou, Guangzhou, Hangzhou, Hengyang, Nanjing, Shanghai, Shantou, Shenzhen, Zhuhai

  99. Recruiting
    Regional Radiotherapy Omission in Low-Risk Node Positive Breast Cancer
    Phase
    Not given
    Started
    2022-07
    Posted
    Registry
    NCT07179744

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  100. Recruiting
    Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer
    Phase
    Phase 3
    Started
    2021-04
    Posted
    Registry
    NCT04722978

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  101. Recruiting
    Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
    Phase
    Phase 4
    Started
    2021-06
    Posted
    Registry
    NCT04790305

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Wuhan, Xi'an, Yangzhou, Zhengzhou

  102. Recruiting
    A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC
    Phase
    Phase 2/Phase 3
    Started
    2021-04
    Posted
    Registry
    NCT04803539

    Age 18 years to 80 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  103. Recruiting
    Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2021-01
    Posted
    Registry
    NCT04842812

    Age 18 years to 85 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  104. Recruiting
    Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
    Phase
    Phase 3
    Started
    2021-12
    Posted
    Registry
    NCT05159193

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  105. Recruiting
    Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Posted
    Registry
    NCT05187338

    Age 18 years to 70 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  106. Recruiting
    A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC
    Phase
    Phase 2
    Started
    2020-08
    Posted
    Registry
    NCT04501523

    Age 18 years to 80 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  107. Recruiting
    Study of PF-07248144 in Advanced or Metastatic Solid Tumors
    Phase
    Phase 2
    Started
    2020-11
    Posted
    Registry
    NCT04606446

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Xi'an

  108. Recruiting
    Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2020-10
    Posted
    Registry
    NCT04646759

    Age 18 years to 80 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  109. Recruiting
    RecurIndex Guided Avoidance of Regional Nodal Irradiation for Node Positive Breast Cancer
    Phase
    N/A
    Started
    2019-08
    Posted
    Registry
    NCT04069884

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  110. Recruiting
    Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
    Phase
    Phase 2/Phase 3
    Started
    2018-11
    Posted
    Registry
    NCT03755739

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  111. Recruiting
    Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2018-05
    Posted
    Registry
    NCT04263298

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChangsha, Guangzhou, Nanning, Shantou, Shenzhen, Zhanjiang

  112. Not yet recruiting
    A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07235618

    Age 18 years to 75 years; women only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  113. Not yet recruiting
    Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)
    Phase
    Phase 2
    Started
    2026-11
    Posted
    Registry
    NCT07255612

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  114. Not yet recruiting
    Pedicled Lateral Chest Wall Lymph-Adipofascial Flap to Prevent Arm Lymphedema After Breast Cancer Surgery
    Phase
    N/A
    Started
    2026-02
    Posted
    Registry
    NCT07415200

    Age 18 years to 75 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  115. Not yet recruiting
    Effects of Instrument-Assisted Constant-Speed Injection Versus Manual Injection on Pain From Large-Volume Subcutaneous Injection of Pertuzumab and Trastuzumab in Breast Cancer: A Randomized, Self-Controlled Study
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07533526

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  116. Not yet recruiting
    Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07539753

    Age 18 years to 75 years; women only (registered criteria)

    Led by Nanfang HospitalGuangzhou

  117. Not yet recruiting
    Ultrasound Monitoring of Clipped Lymph Nodes to Predict Axillary Response After Chemotherapy in Breast Cancer
    Phase
    Not given
    Started
    2026-05
    Posted
    Registry
    NCT07596472

    Age 18 years to Not stated; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  118. Not yet recruiting
    Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07630103

    Age 18 years to 75 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  119. Not yet recruiting
    Molecular Subtype-Guided Postoperative Radiotherapy for Phyllodes Tumor of the Breast
    Phase
    N/A
    Started
    2026-10
    Posted
    Registry
    NCT07657169

    Age 18 years to 75 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 3 listed hospitals as study sitesGuangzhou, Jinan, Qingdao, Shenzhen

  120. Not yet recruiting
    Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07745257

    Age 18 years to 80 years; women only (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 8 listed hospitals as study sitesAnyang, Chengdu, Dalian, Guangzhou, Hangzhou, Nanchang, Nanjing, Shijiazhuang, Zhengzhou

  121. Not yet recruiting
    Research on the Development and Validation of Personalized Exercise Prescription System for Breast Cancer Patients Based on Large Language Models
    Phase
    Not given
    Started
    2026-09
    Posted
    Registry
    NCT07767565

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  122. Not yet recruiting
    Impact of Robotic Versus Endoscopic Surgery on Nipple Nerve Function Following Nipple-Sparing Mastectomy for Breast Cancer
    Phase
    N/A
    Started
    2026-10
    Posted
    Registry
    NCT07850154

    Age not stated (registered criteria)

    Led by Guangzhou Women and Children's Medical CenterGuangzhou

  123. Not yet recruiting
    A Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080
    Phase
    Phase 1
    Started
    2026-11
    Posted
    Registry
    NCT07876596

    Age 18 years to 55 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  124. Not yet recruiting
    Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2026-11
    Posted
    Registry
    NCT07892274

    Age 18 years to 80 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  125. Not yet recruiting
    Multimodal LLM for Breast Cancer Radiotherapy Target Auto-Contouring and Planning
    Phase
    Not given
    Started
    2026-11
    Posted
    Registry
    NCT07943494

    Age not stated (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  126. Not yet recruiting
    This Study Aims to Explore the Efficacy of Hyperbaric Oxygen in the Treatment of Flap Ischaemic Necrosis After Breast Cancer Surgery
    Phase
    N/A
    Started
    2025-01
    Posted
    Registry
    NCT06811857

    Age 18 years to 60 years; women only (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  127. Not yet recruiting
    Hyperbaric Oxygen Therapy for Peripheral Neuropathy Due to Paclitaxel Analogs
    Phase
    N/A
    Started
    2025-02
    Posted
    Registry
    NCT06819501

    Age 18 years to 60 years; women only (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  128. Not yet recruiting
    A Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Hormone Receptor Positive Breast Cancer Patients
    Phase
    N/A
    Started
    2025-02
    Posted
    Registry
    NCT06825949

    Age 18 years to 60 years; women only (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  129. Not yet recruiting
    A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Triple-Negative and HER2+ Breast Cancer Patients
    Phase
    N/A
    Started
    2025-02
    Posted
    Registry
    NCT06825975

    Age 18 years to 60 years; women only (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  130. Not yet recruiting
    A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07040644

    Age 18 years to Not stated; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  131. Not yet recruiting
    Human-AI Collaborative INSIGHT Diagnostic Workflow for in Breast Cancer With Extensive Intraductal Component
    Phase
    N/A
    Started
    2025-08
    Posted
    Registry
    NCT07060599

    Age not stated; women only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  132. Not yet recruiting
    Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07061717

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  133. Not yet recruiting
    Fasting-Mimicking Diet as an Adjunct to Neoadjuvant Chemotherapy for Hormone-Receptor-Positive Breast Cancer
    Phase
    N/A
    Started
    2025-07
    Posted
    Registry
    NCT07077018

    Age 18 years to 75 years (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  134. Not yet recruiting
    Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07246317

    Age 18 years to 70 years; women only (registered criteria)

    Led by Tianjin Medical University Cancer Institute & Hospital; 4 listed hospitals as study sitesGuangzhou, Luoyang, Shijiazhuang, Tianjin

  135. Not yet recruiting
    Myeloprotection With Trilaciclib in Pan-cancer Population
    Phase
    Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06297811

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  136. Not yet recruiting
    Aromatherapy in the Treatment of Early Breast Cancer
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06435104

    Age 18 years to 80 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  137. Enrolling by invitation
    Endoscopic Nipple-Sparing Mastectomy (E-NSM) With Immediate Multistage Autologous Fat Grafting(IMAFG) for Total Breast Reconstruction Via the Axillary Incision
    Phase
    N/A
    Started
    2026-01
    Posted
    Registry
    NCT07352137

    Age 18 years to 70 years; women only (registered criteria)

    Led by Guangdong Provincial Hospital of Chinese MedicineGuangzhou

  138. Enrolling by invitation
    Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06843681

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  139. Enrolling by invitation
    A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07376629

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesAnyang, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanjing, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Disease research in Guangzhou

Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.

A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.

Papers led and open trials led by hospitals in Guangzhou, by disease
CancerBlood disordersOther diseases
HospitalNasopharyngeal carcinomaOesophageal squamous cell carcinomaHepatocellular carcinomaStomach cancerLung cancerPancreatic cancerBreast cancerGliomaHepatoblastomaRetinoblastomaChordomaOsteosarcomaGastrointestinal stromal tumourNeuroblastomaEwing sarcomaMultiple myelomaB-cell acute lymphoblastic leukaemiaAplastic anaemiaHaemophagocytic lymphohistiocytosisLymphomaBeta thalassaemiaHaemophilia AAtypical haemolytic uraemic syndromeThrombotic thrombocytopenic purpuraFanconi anaemiaNeuromyelitis optica spectrum disorderIgG4-related diseaseMyasthenia gravisMoyamoya diseaseWilson diseaseBiliary atresiaCoronary heart diseaseCongenital heart diseaseScoliosisAnti-NMDA receptor encephalitisTakayasu arteritisHepatic echinococcosisIdiopathic pulmonary fibrosisLymphangioleiomyomatosisAmyotrophic lateral sclerosisSpinal muscular atrophyFabry diseasePompe diseaseDuchenne muscular dystrophyBehçet diseaseAlport syndromeIgA nephropathyGaucher diseaseNiemann–Pick disease type COsteogenesis imperfectaPrimary biliary cholangitisPrimary sclerosing cholangitisCongenital diaphragmatic herniaHirschsprung diseaseInherited epidermolysis bullosaHereditary angioedemaFamilial adenomatous polyposisLeber hereditary optic neuropathyMajeed syndromeNGLY1 deficiencyISG15 deficiencyShortlist
Affiliated Brain Hospital of Guangzhou Medical University广州医科大学附属脑科医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Cancer Hospital of Guangzhou Medical University广州医科大学附属肿瘤医院291 open1311828none3015nonenonenone0none102nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Hospital of Southern China University of Technology华南理工大学医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Hospital, Sun Yat-sen University中山大学附属口腔医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Air Force Hospital中国人民解放军南部战区空军医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Children Hospital广东省妇幼保健院nonenonenonenonenonenone13nonenonenonenone1none01nonenonenonenonenone7nonenonenonenonenonenonenonenonenonenonenone4nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone02nonenonenonenonenonenonenone
Children's Medical Center广州医科大学附属妇女儿童医疗中心nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenone
Clifford Hospitalnonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Dermatology Hospital上海市皮肤病医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenone1nonenonenonenonenonenone
Dermatology Hospital, Southern Medical University南方医科大学皮肤病医院、广东省皮肤病医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenone
Eighth People's Hospital of Guangzhou Affiliated to Guangzhou Medical College广州医科大学附属市八医院nonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fifth Affiliated Hospital of Guangzhou Medical University广州医科大学附属第五医院15nonenone22nonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenone
Fifth Affiliated Hospital of Southern Medical University南方医科大学第五附属医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Affiliated Hospital of Guangdong Pharmaceutical University广东药科大学附属第一医院4nonenonenonenonenonenonenonenonenonenone0none1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Affiliated Hospital of Guangzhou Medical University广州医科大学附属第一医院63nonenone18621 opennonenonenonenonenonenone0none1nonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenone2none00none213nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenone0nonenonenonenone
First Affiliated Hospital of Guangzhou University of Chinese Medicine广州中医药大学第一附属医院2none321235none4nonenonenonenone2nonenonenone2nonenonenone700nonenonenonenonenone6nonenonenone4nonenonenone1none4nonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Affiliated Hospital of Jinan University暨南大学附属第一医院165451 open2159none5730none0none912none5nonenonenone52nonenonenonenonenonenone4none2none76none0nonenone1nonenonenonenonenonenonenone10nonenonenonenonenonenone22nonenonenonenonenonenone
First Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院143 open201 open2196 open527139491 open391 open5103392 open01181none235nonenonenonenone2none284612211 open61 open52019none2400540222 open0nonenone10none1none00nonenonenonenone
Fuda Cancer Hospital广州复大肿瘤医院0none000000nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangdong Clifford Hospital广东祈福医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangdong Province Hospital for Occupational Disease Prevention and Treatment广东省职业病防治院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangdong Provincial Hospital of Chinese Medicine广东省中医院5none2512416501 open12nonenonenone2131nonenonenonenonenone0nonenonenonenone4none0nonenonenone157none0nonenone214nonenonenonenonenonenone6nonenonenone2nonenonenonenonenonenonenonenonenonenone
Guangdong Provincial People's Hospital广东省人民医院1419541 open211 open23619 open441 open9610 open431211110none31nonenone231nonenonenonenone331nonenonenone652 open80nonenone0none2none1none1nonenone1none81 opennonenonenone41nonenonenonenonenonenonenonenonenone
Guangdong Provincial Second Hospital广东省第二中医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangdong Second Provincial General Hospital广东省第二人民医院3none16nonenonenonenonenonenonenonenone2none1none31 opennonenone21nonenonenonenonenonenonenonenonenonenonenonenonenonenone4nonenone1none1nonenonenone10nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangzhou Chest Hospital广州市胸科医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangzhou Dongsheng Hospital广州市东升医院(广州市老年病康复医院)nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangzhou Eighth People's Hospital广州市第八人民医院(嘉禾院区)nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenone
Guangzhou First People's Hospital广州市第一人民医院4none2212none1120nonenonenonenone401none0none13none71nonenone11nonenonenonenonenonenonenonenonenone41none2nonenonenonenonenone2nonenone10nonenone0nonenonenonenonenonenonenonenonenonenone
Guangzhou General Hospital中国人民解放军南部战区总医院nonenonenonenonenonenonenonenonenonenonenone0none00nonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangzhou Hospital广州市中西医结合医院nonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangzhou Orthopedics Hospital广州市正骨医院nonenonenonenonenonenonenonenonenonenonenone0nonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangzhou Panyu Central Hospital广州医科大学附属番禺中心医院0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangzhou Red Cross Hospital广州市红十字会医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenone
Guangzhou Women and Children's Medical Center广州市妇女儿童医疗中心2nonenonenone5none161 open1393none10321 opennonenone21 opennonenonenone191 open0nonenonenone1nonenonenone21973423nonenone1none0nonenone12none201none1none0117nonenonenonenonenonenonenone
Hexian Memorial Hospital广州市番禺区妇幼保健院nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenone
Huadu Distinct People's Hospital广州市花都区人民医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Integrated Hospital, Southern Medical University南方医科大学中西医结合医院7nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Nanfang Hospital南方医科大学南方医院336 open84 open1277 open12812 open835 open8832 open531 open00none622none38nonenone192191nonenone3none16nonenone13107nonenone5none612none0none051 opennonenonenone1none10nonenone2nonenonenonenone
Panyu Hospital广州市番禺区中医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Second Affiliated Hospital of Guangzhou Medical University广州医科大学附属第二医院4none3918 open41 open1315 open64 open84 open14nonenonenone1none1none50nonenone220nonenonenone2nonenonenonenonenonenone4none0nonenone3nonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenone0nonenonenonenonenone
Sixth Affiliated Hospital of Guangzhou Medical University清远市人民医院3nonenonenonenonenonenone12nonenonenone2nonenonenonenonenonenonenonenone1nonenone1nonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Sixth Affiliated Hospital of Sun Yat-sen University中山大学附属第六医院none0none455 opennone7161 opennonenone0none13nonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1none41nonenonenone1none01none0nonenonenonenone
Sun Yat-sen Memorial Hospital中山大学孙逸仙纪念医院255 open102 open6610 open115 open362 open3413548 open112nonenone60101 open214none476nonenonenonenone01 open4nonenonenonenone2924nonenone1nonenone3nonenonenonenone1none7nonenone000nonenonenonenonenonenonenonenonenone
Sun Yat-sen University Cancer Center中山大学肿瘤防治中心48357 open1378 open28118 open1034 open35732 open553 open22217 open621 open01 opennone0191 open275 open31 open163none114225 open1nonenonenone0nonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Third Affiliated Hospital of Guangzhou Medical University广州医科大学附属第三医院4nonenonenonenone20nonenonenonenonenone4none0nonenonenonenonenonenone50nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1none1nonenonenone1nonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenone
Third Affiliated Hospital of Guangzhou University of Chinese Medicine广州中医药大学第三附属医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Third Affiliated Hospital of Southern Medical University南方医科大学第三附属医院8nonenonenonenonenonenonenonenonenonenone9nonenone031 opennonenonenone21 opennonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Third Affiliated Hospital of Sun Yat-sen University中山大学附属第三医院10none1713 open15none619none1nonenone201none4nonenone160nonenonenone1392 opennone01 open30none9none4222none1none2nonenonenonenone010none0none21nonenonenone0nonenonenonenonenone
Third People's Hospital, Guangzhou Medical Universitynonenonenonenone01 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Zhongshan Ophthalmic Center中山大学中山眼科中心nonenonenonenonenonenonenonenonenone251 opennonenonenone0nonenonenonenonenone41 opennonenonenonenonenone4nonenonenonenonenonenone81nonenonenonenonenonenonenonenonenonenone7nonenonenonenonenonenonenonenonenonenonenonenone3nonenonenone
Zhujiang Hospital南方医科大学珠江医院114545 open10691 open2124661 opennone119none6none23 open12 opennonenone101 open1nonenonenonenonenonenonenonenonenonenone7nonenonenonenonenonenonenone1nonenonenonenonenonenone2nonenonenonenonenonenone5nonenonenonenonenonenonenone

Column labels are short names. Choose one to open that disease in Guangzhou.

Other cities nearby

Straight-line distance from the city centre; counts are hospitals listed for breast cancer.

Counts are listed hospitals only, not every hospital in each city.

Where these numbers come from

Papers

English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions

Trials

ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Guangzhou on ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data